[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Madrigal Pharmaceuticals Inc (MDGL)

Madrigal Pharmaceuticals Inc (MDGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,759,478
  • Shares Outstanding, K 23,056
  • Annual Sales, $ 958,400 K
  • Annual Income, $ -288,280 K
  • EBIT $ -300 M
  • EBITDA $ -294 M
  • 60-Month Beta -1.04
  • Price/Sales 12.87
  • Price/Cash Flow N/A
  • Price/Book 20.16

Options Overview Details

View History
  • Implied Volatility 39.61% (-0.40%)
  • Historical Volatility 36.22%
  • IV Percentile 1%
  • IV Rank 8.45%
  • IV High 73.99% on 11/03/25
  • IV Low 36.43% on 05/06/26
  • Expected Move (DTE 5) 15.45 (3.03%)
  • Put/Call Vol Ratio 1.02
  • Today's Volume 870
  • Volume Avg (30-Day) 537
  • Put/Call OI Ratio 0.38
  • Today's Open Interest 20,531
  • Open Int (30-Day) 16,345
  • Expected Range 494.59 to 525.49

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.44
  • Number of Estimates 7
  • High Estimate $0.04
  • Low Estimate $-2.84
  • Prior Year $-1.90
  • Growth Rate Est. (year over year) +24.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
497.23 +2.58%
on 05/05/26
559.00 -8.76%
on 05/06/26
-9.71 (-1.87%)
since 04/08/26
3-Month
416.21 +22.54%
on 03/03/26
572.20 -10.86%
on 03/26/26
+32.44 (+6.79%)
since 02/06/26
52-Week
265.00 +92.47%
on 05/27/25
615.00 -17.07%
on 12/24/25
+210.47 (+70.26%)
since 05/08/25

Most Recent Stories

More News
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 510.04 (-4.64%)
Madrigal: Q1 Earnings Snapshot

Madrigal: Q1 Earnings Snapshot

MDGL : 510.04 (-4.64%)
Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates

First-quarter 2026 Rezdiffra ® (resmetirom) net sales of $311.3 million, representing year-over-year growth of 127% As of  March 31, 2026, more than 42,250 patients on Rezdiffra, up...

MDGL : 510.04 (-4.64%)
Madrigal's First Full Quarter of Rezdiffra Sales With Nowhere Left to Hide

Barchart Research What to Expect from MDGL Earnings MDGL Generated May 5, 2026 Current Price $502.47 EPS Estimate $$-3.61 Consensus Rating Strong Buy Average Move 10.52% Madrigal's First Full Quarter of...

MDGL : 510.04 (-4.64%)
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

- Precision approach targets patients who have a mutation in the PNPLA3 gene, which is highly prevalent among Hispanic patients with MASH - Phase 1 data published in The New England...

ARWR : 72.69 (-6.75%)
MDGL : 510.04 (-4.64%)
Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline

Company advances its leadership in MASH with clinical-stage, genetically targeted siRNA asset from Arrowhead Pharmaceuticals Precision approach targets patients who have a mutation in the PNPLA3 gene,...

MDGL : 510.04 (-4.64%)
Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026

CONSHOHOCKEN, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2026 financial results on Wednesday, May 6,...

MDGL : 510.04 (-4.64%)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 510.04 (-4.64%)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 510.04 (-4.64%)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 510.04 (-4.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-' agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia...

See More

Key Turning Points

3rd Resistance Point 562.64
2nd Resistance Point 552.11
1st Resistance Point 531.07
Last Price 510.04
1st Support Level 499.50
2nd Support Level 488.97
3rd Support Level 467.93

See More

52-Week High 615.00
Last Price 510.04
Fibonacci 61.8% 481.30
Fibonacci 50% 440.00
Fibonacci 38.2% 398.70
52-Week Low 265.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.